Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010 (EXCEL)

This study has been completed.
Sponsor:
Information provided by:
Takeda
ClinicalTrials.gov Identifier:
NCT00175019
First received: September 12, 2005
Last updated: July 22, 2010
Last verified: July 2010
  Purpose

The purpose of this study is to determine the long-term safety of febuxostat, once daily (QD), compared to allopurinol in reducing serum urate levels in subjects with gout.


Condition Intervention Phase
Gout
Drug: Febuxostat
Drug: Allopurinol
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 3, Open-Label, Randomized, Allopurinol-Controlled Study to Assess the Long-Term Safety of Oral Febuxostat in Subjects With Gout

Resource links provided by NLM:


Further study details as provided by Takeda:

Primary Outcome Measures:
  • Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 1. [ Time Frame: Month 1 ] [ Designated as safety issue: No ]
    Serum urate values were obtained at the Month 1 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 1 visit was summarized.

  • Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 12. [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
    Serum urate values were obtained at the Month 12 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 12 visit was summarized.

  • Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 24. [ Time Frame: Month 24 ] [ Designated as safety issue: No ]
    Serum urate values were obtained at the Month 24 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 24 visit was summarized.

  • Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 36. [ Time Frame: Month 36 ] [ Designated as safety issue: No ]
    Serum urate values were obtained at the Month 36 visit. The percentage of subjects whose serum urate was <6.0 mg/dL at the Month 36 visit was summarized.

  • Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Last Visit on Treatment. [ Time Frame: Last Visit on treatment (up to 40 months). ] [ Designated as safety issue: No ]
    The percentage of subjects whose serum urate was <6.0 mg/dL at the last visit on treatment was summarized. The last visit on treatment was the last visit at which a serum urate value was collected prior to any changes in drug and/or dose from the initial treatment assignment.


Secondary Outcome Measures:
  • Percent Change in Serum Urate Levels From Baseline to the Last Visit on Treatment. [ Time Frame: Last Visit on treatment (up to 40 months). ] [ Designated as safety issue: No ]
    The percent change in serum urate from baseline to the last visit on treatment was summarized. The last visit on treatment was the last visit at which a serum urate value was collected prior to any changes in drug and/or dose from the initial treatment assignment.

  • Percent Change From Baseline in Primary Tophus Size at Month 12 for Subjects With Palpable Tophi Measured at Baseline. [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
    The area of the primary tophus was calculated based on the length and width of the tophus measured at the Month 12 visit. The percent change from baseline in primary tophus size to the Month 12 visit was summarized.

  • Percent Change From Baseline in Primary Tophus Size at Month 24 for Subjects With Palpable Tophi Measured at Baseline. [ Time Frame: Month 24 ] [ Designated as safety issue: No ]
    The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and Month 24 visit. The percent change from baseline in primary tophus size to the Month 24 visit was summarized.

  • Percent Change From Baseline in Primary Tophus Size at Month 36 for Subjects With Palpable Tophi Measured at Baseline. [ Time Frame: Month 36 ] [ Designated as safety issue: No ]
    The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and Month 36 visit. The percent change from baseline in primary tophus size to the Month 36 visit was summarized.

  • Percent Change From Baseline in Primary Tophus Size at Final Visit for Subjects With Palpable Tophi Measured at Baseline. [ Time Frame: Final Visit (up to 40 months). ] [ Designated as safety issue: No ]
    The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and final visit. The percent change from baseline in primary tophus size to the final visit was summarized.

  • Percent Change From Baseline in the Total Number of Tophi for Subjects With Palpable Tophi at Final Visit. [ Time Frame: Final Visit (up to 40 months). ] [ Designated as safety issue: No ]
    The number of tophi were counted at baseline and final visits. The percent change from baseline in the number of tophi to the final visit was summarized.

  • Percentage of Subjects Requiring Treatment for Gout Flare up to Month 12. [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
    The percentage of subjects requiring treatment for gout flare during the first twelve months of final stable treatment was summarized.

  • Percentage of Subjects Requiring Treatment for Gout Flare After Month 12. [ Time Frame: After Month 12 to Final Visit ] [ Designated as safety issue: No ]
    The percentage of subjects requiring treatment for gout flare after the first 12 months of final stable treatment was summarized.


Enrollment: 1086
Study Start Date: July 2003
Study Completion Date: February 2007
Primary Completion Date: February 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Febuxostat 80 mg QD Drug: Febuxostat
Febuxostat 80 mg, tablets, orally, once daily.
Other Names:
  • TMX-67
  • Tei-6720
  • Uloric
Experimental: Febuxostat 120 mg QD Drug: Febuxostat
Febuxostat 120 mg, tablets, orally, once daily.
Other Names:
  • TMX-67
  • Tei-6720
  • Uloric
Active Comparator: Allopurinol QD Drug: Allopurinol
Allopurinol 100 mg or 300 mg, tablets, orally, once daily.
Other Name: Zyloprim

Detailed Description:

Uric acid is the end product of purine degradation in humans. Hyperuricemia, a urate concentration in serum exceeding the limit of urate solubility (approximately 7.0 mg/dL), is a common biochemical abnormality. Aberrations in any of the multiple mechanisms involved in the production and/or excretion of uric acid may increase serum urate concentrations, with persistent hyperuricemia as a marker for extracellular fluid monosodium urate supersaturation. As such, hyperuricemia is a necessary (but often insufficient) risk factor for monosodium urate crystal deposition in tissues and is the fundamental pathophysiological process underlying the clinical manifestations of gout, which is a chronic disease characterized by urate crystal formation and deposition in joints and bones. Gout may progress from episodic attacks of acute inflammatory arthritis to a disabling chronic disorder characterized by deforming arthropathy; destructive deposits of urate crystals (tophi) in bones, joints, and other organs; structural and functional renal impairment due to interstitial urate crystal deposition; and urinary tract stones composed entirely or partially of uric acid crystals. Management of gout requires chronic treatment aimed at lowering serum urate levels into a subsaturating range (usually <6.0 mg/dL) in which crystal formation and deposition are prevented or reversed.

Febuxostat (TMX-67) is a non-purine selective xanthine oxidase inhibitor being developed as an orally administered agent for the management of hyperuricemia in patients with gout.

This study was originally designed and initiated having all subjects initially assigned to 80 mg febuxostat provided as an 80 mg tablet, to be administered orally. Subjects could be titrated to 120 mg, provided as one 40 and 80 mg tablet, between Months 2 and 6, if their serum uric acid rose > 6.0 mg/dL; the dose could be down-titrated to 80 mg if the serum uric acid decreased to < 3.0 mg/dL.

The protocol was amended to add a comparator arm, and to have subjects randomized to 80 or 120 mg febuxostat or allopurinol (100 or 300 mg, dependent on renal function). The information below reflects the treatments following the implementation of the revised protocol.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Is receiving thiazide diuretic therapy (only to subjects randomized to or receiving febuxostat).
  • Has a serum urate level less than 8.0 mg/dL and is not taking uric acid-lowering therapy (other than allopurinol or febuxostat).
  • Has participated in a clinical study in which febuxostat was administered.
  • Is completing Phase 3 Studies C02-009 or C02-010.
  • Must not have experienced any serious study drug-related adverse events in the previous study.
  • Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study

Exclusion Criteria:

  • Has had any other significant medical condition as defined by the investigator that would interfere with the treatment, safety, or compliance with the protocol.
  • Is intolerant of allopurinol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00175019

Sponsors and Collaborators
Takeda
Investigators
Study Chair: Medical Director Takeda
  More Information

Additional Information:
Publications:
Responsible Party: Sr. VP, Clinical Science, Takeda Global Research & Development Center, Inc.
ClinicalTrials.gov Identifier: NCT00175019     History of Changes
Other Study ID Numbers: C02-021, U1111-1113-9814
Study First Received: September 12, 2005
Results First Received: March 12, 2009
Last Updated: July 22, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Takeda:
uric acid
xanthine oxidase
hyperuricemia
tophi
Drug Therapy

Additional relevant MeSH terms:
Allopurinol
Febuxostat
Antimetabolites
Antioxidants
Antirheumatic Agents
Enzyme Inhibitors
Free Radical Scavengers
Gout Suppressants
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on October 20, 2014